drugset / Trial / NCT00964561

Ph1 Study of Valortim and Ciprofloxacin in Humans

NCT00964561

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of short-term dosing of IV ciprofloxacin when administered concomitantly with IV Valortim in healthy normal human subjects.

Timeline

Start
2009-08
Primary completion
2010-02
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 400 mg Intravenous
Subject MDX-1303 Monoclonal antibody 20 mg/kg Intravenous

Indications